Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
| Title: | Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. |
|---|---|
| Authors: | Wong A; Department of Cardiology, National Heart Centre, Singapore. aaron_wong@nhc.com.sg; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL |
| Source: | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2004 Aug; Vol. 62 (4), pp. 445-52. |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 100884139 Publication Model: Print Cited Medium: Internet ISSN: 1522-726X (Electronic) Linking ISSN: 15221946 NLM ISO Abbreviation: Catheter Cardiovasc Interv Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Wiley-Liss, c1999- |
| MeSH Terms: | Angioplasty, Balloon, Coronary*/adverse effects ; Angioplasty, Balloon, Coronary*/instrumentation ; Stents*; Antibodies, Monoclonal/*therapeutic use ; Fibrinolytic Agents/*therapeutic use ; Immunoglobulin Fab Fragments/*therapeutic use ; Myocardial Infarction/*therapy ; Platelet Aggregation Inhibitors/*therapeutic use ; Tissue Plasminogen Activator/*therapeutic use; Antibodies, Monoclonal/adverse effects ; Cardiovascular Diseases/etiology ; Fibrinolytic Agents/administration & dosage ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Immunoglobulin Fab Fragments/adverse effects ; Myocardial Infarction/diagnostic imaging ; Myocardial Infarction/drug therapy ; Myocardial Infarction/physiopathology ; Platelet Aggregation Inhibitors/adverse effects ; Tissue Plasminogen Activator/administration & dosage ; Tissue Plasminogen Activator/adverse effects ; Abciximab ; Aged ; Combined Modality Therapy ; Coronary Angiography ; Coronary Circulation ; Drug Therapy, Combination ; Feasibility Studies ; Female ; Humans ; Male ; Middle Aged ; Pilot Projects ; Research Design ; Singapore ; Time Factors ; Treatment Outcome |
| Abstract: | We conducted a randomized feasibility pilot study comparing combined fibrinolysis with immediate rescue angioplasty vs. primary angioplasty with adjunctive abciximab in patients with acute myocardial infarction (AMI). Seventy patients with ST segment elevation AMI of |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal); 0 (Fibrinolytic Agents); 0 (Immunoglobulin Fab Fragments); 0 (Platelet Aggregation Inhibitors); EC 3.4.21.68 (Tissue Plasminogen Activator); X85G7936GV (Abciximab) |
| Entry Date(s): | Date Created: 20040727 Date Completed: 20080207 Latest Revision: 20260128 |
| Update Code: | 20260130 |
| DOI: | 10.1002/ccd.20101 |
| PMID: | 15274152 |
| Database: | MEDLINE |
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't